TargetIL6ST/CD130Purity>97% by SDS-PAGEMol. weight68.2 kDaActivityMeasured by its ability to inhibit the IL6 Rα enhancement...SpeciesRat
Measured by its ability to inhibit the IL6 Rα enhancement of IL6 activity on M1 mouse myeloid leukemia cells. The ED50 for this effect is typically 0.5-2 μg/ml in the presence of 50 ng/ml recombinant human IL6sR and 100 ng/ml recombinant human IL6.HEK293 Cells< 1.0 EU per μg of the protein as determined by the LAL method.
TargetIL6ST/CD130Purity>95% by SDS-PAGEMol. weight96.0 kDaActivityMeasured by its ability to inhibit the IL-6Rα enhancement...SpeciesHuman
Measured by its ability to inhibit the IL-6Rα enhancement of IL-6 activity on M1 mouse myeloid leukemia cell. The ED50 for this effect is typically 0.2-0.8 μg/mL in the presence of 50 ng/mL recombinant human IL-6sR and 100 ng/mL recombinant human IL-6.HEK293 Cells< 1.0 EU per μg of the protein as determined by the LAL method.
TargetIL6ST/CD130Purity>95% by SDS-PAGEMol. weight94.3 kDaActivityMeasured by its ability to inhibit the IL6 Rα enhancement...SpeciesRat
Measured by its ability to inhibit the IL6 Rα enhancement of IL6 activity on M1 mouse myeloid leukemia cells. The ED50 for this effect is typically 0.015-0.075 μg/ml in the presence of 50 ng/ml recombinant human IL6sR and 100 ng/ml recombinant human IL6.HEK293 Cells< 1.0 EU per μg of the protein as determined by the LAL method.
TargetIL6ST/CD130Purity>97% by SDS-PAGEMol. weight68.0 kDaActivityMeasured by its ability to inhibit the IL-6Rα enhancement...SpeciesMouse
Measured by its ability to inhibit the IL-6Rα enhancement of IL-6 activity on M1 mouse myeloid leukemia cells. The ED50 for this effect is typically 0.6-3 μg/mL in the presence of 50 ng/mL recombinant human IL-6sR and 100 ng/mL recombinant human IL-6.HEK293 Cells< 1.0 EU per μg of the protein as determined by the LAL method.
![Anti-Mouse IL6ST Antibody [B413] - ABMIUM](http://www.abmium.com/cdn/shop/files/shgVWveb_5bbba0d0-3323-4372-a43e-74706ab1e082.jpg?v=1781564014&width=480)
